Inflammatory choroidal neovascular membrane in posterior uveitis-pathogenesis and treatment

Indian Journal of Ophthalmology

Volumn 58, Issue 1, 2010, Pages 3-10

  Dhingra, Narendra ^a   Kelly, Susan ^a   Majid, Mohammed A ^a   Bailey, Claire B ^a   Dick, Andrew D ^a  

^a BRISTOL EYE HOSPITAL   (United Kingdom)

Author keywords

Choroidal neovascular membrane; Immunosuppression; Photodynamic therapy; Posterior segment intraocular inflammation; Posterior uveitis

Indexed keywords

GLUCOCORTICOID;

ANIMAL; EYE SURGERY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LASER COAGULATION; METHODOLOGY; PHOTOTHERAPY; PROGNOSIS; REVIEW; SUBRETINAL NEOVASCULARIZATION; UVEITIS;

ANIMALS; CHOROIDAL NEOVASCULARIZATION; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSION; LASER COAGULATION; OPHTHALMOLOGIC SURGICAL PROCEDURES; PHOTOTHERAPY; PROGNOSIS; UVEITIS, POSTERIOR;

EID: 73849148967     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.58467     Document Type: Review

References (52)

1. Gass JD. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Am J Ophthalmol 1994;118:285-298
2. O'Toole L, Tufail A, Pavesio C. Management of choroidal neovascularization in uveitis. Int Ophthalmol Clin 2005;45:157-177
3. Breger AS, Conway M, del Priore LV, Walker RS, Pollack JS, Kaplan HJ. Submacular surgery for subfoveal choroidal neovascular membranes in patients with presumed ocular histoplasmosis. Arch Ophthalmol 1997;115:991-996
4. Gass JD. Stereoscopic atlas of macular diseases; Diagnosis and treatment. Vol.1. St Louis (MO): Mosby Publishers; 1987.
5. Patel M, Chan CC. Immunopathological aspects of age-related macular degeneration. Semin Immunopathol 2008;30:97-110.
6. Hageman GS, Luthert PJ, Chong VNH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001;20:705-732
7. Kikuchi M, Nakamura M, Ishikawa K, Suzuki T, Nishihara H, Yamakoshi T, et al. Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration. Ophthalmology 2007;114:1722-1727
8. Sivaprasad S, Chong NV, Bailey TA. Serum elastin-derived peptides in age-related macular degeneration. Invest Ophthalmol Vis Sci 2005;46:3046-3051 (Pubitemid 44268947)
9. Forrester JV, Lumsden L, Duncan L, Dick AD. Choroidal dendritic cells require activation to present antigen and resident choroidal macrophages potentiate this response. Br J Ophthalmol 2005;89:369-377
10. Majid MA, Smith VA, Matthews FJ, Newby AC, Dick AD. Tissue inhibitor of metalloproteinase-3 differentially binds to components of Bruch's membrane. Br J Ophthalmol 2006;90:1310-1315
11. Bora, PS, Sohn, JH, Cruz JM, Jha P, Nishihori H, Wang Y, et al. Role of complement and complement membrane attack complex in laserinduced choroidal neovascularization. J Immunol 2005;174:491-497
12. Brito BE, O.Rourke LM, Pan Y, Anglin J, Planck SR, Rosenbaum JT. IL-1 and TNF receptor-deficient mice show decreased inflammation in an immune complex model of uveitis. Invest Ophthalmol Vis Sci 1999;40:2583-2589
13. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058-1066
14. Walport MJ Complement. Second of two parts. N Engl J Med 2001;344:1140-1144
15. Chan CC, Li Q. Immunopathology of uveitis. Br J Ophthalmol 1998;82:91-6.
16. Smith JR, Hart PH, Williams KA. Basic pathogenic mechanisms operating in experimental models of acute anterior uveitis. Immunol Cell Biol 1998;76:497-512.
17. Adamus G, Chan CC. Experimental autoimmune uveitides: multiple antigens, diverse diseases. Int Rev Immunol 2002;21: 209-229
18. Dick AD, Carter D, Robertson M, Broderick C, Hughes E, Forrester JV, et al. Control of myeloid activity during retinal inflammation. J Leukoc Biol 2003;74:161-166
19. Smith JR, Hart PH, Williams KA. Basic pathogenic mechanisms operating in experimental models of acute anterior uveitis. Immunol Cell Bio 1998;76:497-512.
20. Ooi KG, Galatowicz G, Calder VL, Lightman SL. Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype? Clin Med Res 2006;4:294-309.
21. Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res 2004;23:617-637
22. Mori K, Gehlbach P, Yamamoto S, Duh E, Zack DJ, Li Q, et al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Visual Sci 2002;43:1994-2000.
23. Mori K, Gehlbach P, Ando A, McVey D, Wei L, Campochiaro PA. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Visual Sci 2002;43:2428-34.
24. Holekamp NM, Bouck N, Volpert O. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularisation due to age-related macular degeneration. Am J Ophthalmol 2002;134:220-227
25. Ambati J, Anand A, Fernandez S, Sakurai E, Lynn BC, Kuziel WA, et al. An animal model of age-related macular degeneration in senescent Ccl-2-or Ccr-2-deficient mice. Nat Med 2003;9:1390-1397
26. Combadiere C, Feumi C, Raoul W, Keller N, Rodéro M, Pézard A, et al. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J Clin Invest 2007;117:2920-2928
27. Tuo J, Bojanowski CM, Zhou M, Shen D, Ross RJ, Rosenberg KI, et al. Murine ccl2/cx3cr1 deficiency results in retinal lesions mimicking human age-related macular degeneration. Invest Ophthalmol Vis Sci 2007;48:3827-3836
28. Ross RJ, Zhou M, Shen D, Fariss RN, Ding X, Bojanowski CM, et al. Immunological protein expression profile in Ccl2/Cx3cr1 deficient mice with lesions similar to age-related macular degeneration. Exp Eye Res 2008;86:675-683
29. Brown J Jr, Folk JC, Reddy CV, Dunn JP, Jabs DA. Visual prognosis of multifocal choroiditis, Punctateinner choroidopathy and the diffuse retinal fibrosis syndrome. Ophthalmology 1996;103:1100-1105
30. Kedhar SR, Thorne JE, Wittenberg S, Dunn JP, Jabs DA. Multifocal choroiditis with panuveitis and puntate inner choroidopathy: Comparison of clinical characteristics at presentation. Retina 2007;27:1174-9.
31. Gerstenblith AT, Thorne JE, Sobrin L, Do DV, Shah SM, Foster CS. Punctateinner choroidopathy: A survey analysis of 77 persons. Ophthalmology 2007;114:1201-1204
32. Kleiner RC, Ratner CM, Enger MS, Fine SL. Subfoveal neovascularisation in the ocular histoplasmosis syndrome: A natural history study. Retina 1988;8:225-229
33. Olk JR, Burgess DB, Mc Cormick PA. Subfoveal and juxtafoveal subretinal neovascularisation in the presumed ocular histoplasmosis syndrome: Visual prognosis. Ophthalmology 1984;91:1592-1602
34. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularisation. Five year results from randomized trials. Arch Ophthalmol 1994;112:500-509
35. Olsen TW, Capone A Jr, Sternberg P Jr, Grossniklaus HE, Martin DF, Aaberg TM Sr. Subfoveal choroidal neovascularisation in punctuate inner choroidopathy. Surgical management and pathologic Findings. Ophthalmology 1996;103:2061-2069
36. Essex RW, Tufail A, Bunce C, Aylward GW. Two year results of surgical removal of choroidal neovascular membranes related to non-age related macular degeneration. Br J Ophthalmol 2007;91:649-654
37. Flaxel CJ, Owens SL, Mulholland B, Schwartz SD, Gregor ZJ. The use of corticosteroids for choroidal neovascularisation in young patients. Eye 1998;12:266-272
38. Martidis A, Miller DG, Ciulla TA, Danis RP, Moorthy RS. Corticosteroids as an antiangiogenic agent for histoplasmosis . related subfoveal choroidal neovascularisation. J Ocul Pharmacol Ther 1999;15:425-428
39. Rechtman E, Allen VD, Danis RP, Pratt LM, Harris A, Speicher MA. Intravitreal triamcinolone for choroidal neovascularisation in ocular histoplasmosis syndrome. Am J Ophthalmol 2003;136:739-741
40. Rosenfeld PJ, Saperstein DA, Bressler NM, Reaves TA, Sickenberg M, Rosa RH Jr, et al. Verteporfin in Ocular Histoplasmosis Study Group. Photodynamic therapy with Verteporfin in ocular histoplasmosis: Uncontrolled, open-label-2-year study. Ophthalmology 2004;111:1725-1733
41. Postelmans L , Pasteels B , Coquelet P, Casper L, Verougstraete C, Leys A, et al. Photodynamic therapy for subfoveal classic choroidal neovascularisation related to punctuate inner choroidopathy (PIC) or presumed ocular histoplasmosis like syndrome (POHS-like). Ocul Immunol Inflamm 2005;13:361-366
42. Leslie T, Lois N, Christopoulou D, Olson JA, Forrester J. Photodynamic therapy for Inflammatory choroidal neovascularisation unresponsive to immunosuppression. Br J Ophthalmol 2005;89:147-150
43. Chan WM, Lai T, Lau T, Lee VY, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone for choroidal neovascularisation secondary to punctuate inner choroidopathy or of idiopathic origin. Retina 2008;28:71-80.
44. Fong KC, Thomas D, Amin K, Inzerillo D, Horgan SE. Photodynamic therapy combined with systemic corticosteroids for choroidal neovascularisation secondary to punctuateinner choroidopathy. Eye 2008;22:528-533
45. Giovannini A, Neri P, Mercanti L, Brue C. Photodynamic treatment versus photodynamic treatment associated with systemic steroids for idiopathic choroidal neovascularisation. Br J Ophthalmol 2007;91:620-623
46. Xiong M, Elson G, Legarda D, Leibovich SJ. Production of vascular endothelial growth factor by murine macrophages: regulation by hypoxia, lactate, and the inducible nitric oxide synthase pathway. Am J Pathol 1999;153:587-598
47. Adan A, Mateo C, Navarro R, Bitrian E, Casaroli-Marano RP. Intravitreal bevacizumab (Avastin) injection as primary treatment of inflammatory choroidal neovascularisation. Retina 2007;27: 1180-1186
48. Chan WM, Lai TM, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to central serous retinopathy, secondary to punctuate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 2007;143:977-983
49. Hogan A, Behan U, Kilmartin DJ. Outcomes after combined photodynamic therapy and immunosuppression for Inflammatory subfoveal choroidal neovascularization, Br J Ophthalmol 2005;89:1109-1111
50. Dees C, Arnold JJ, Forrester JV, Dick AD. Immunosuppressive treatment of choroidal neovascularisation associated with endogenous posterior uveitis. Arch Ophthalmol 1998;116:1456-1461
51. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with Verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999;117:1329-1345
52. Jabs DA. Improving the reporting of clinical case series. Am J Ophthalmol 2005;139:900-905